SavedAdd your journal

Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 3

Evaluating various radiographic methods of shoulder joint damage inpatients with rheumatoid arthritis receiving biologicaldisease-modifying antirheumatic drugs

Kazuhito SUGİMORİ
Isao MATSUSHITA
Tomoatsu KIMURA
Pages
349–359
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thisstudy suggests that MDI and UMI may help to evaluate radiographic progression of damage in shoulder joints in patients on bDMARDs, which isdifficult to detect using the Larsen grade.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to clarify shoulder joint damage in rheumatoid arthritis patients receiving biological disease-modifying antirheumaticdrugs (bDMARDs) and the relationship between joint damage and clinical factors.
📊
Key Findings & Data:Patients and methods: In this retrospective study conducted between April 2005 and December 2008, 36 shoulders in 19 patients (2 males,17 females; mean age: 58.9 years; range 42 to 75 years) were evaluated at baseline and two years after the initiation of bDMARD therapy withinfliximab (n=14) or etanercept (n=5).
💡
Conclusion & Impact:Thisstudy suggests that MDI and UMI may help to evaluate radiographic progression of damage in shoulder joints in patients on bDMARDs, which isdifficult to detect using the Larsen grade.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to clarify shoulder joint damage in rheumatoid arthritis patients receiving biological disease-modifying antirheumaticdrugs (bDMARDs) and the relationship between joint damage and clinical factors. Patients and methods: In this retrospective study conducted between April 2005 and December 2008, 36 shoulders in 19 patients (2 males,17 females; mean age: 58.9 years; range 42 to 75 years) were evaluated at baseline and two years after the initiation of bDMARD therapy withinfliximab (n=14) or etanercept (n=5). Standard anteroposterior radiographs of the shoulder joints were taken at baseline and two years afterinstitution of biological therapy. Structural damage in the shoulder joints was assessed using the Larsen scoring method, the medial displacementindex (MDI), and the upward migration index (UMI). Results: There was a significant correlation between MDI, UMI, and Larsen grade before biological therapy. Univariate analysis revealed that thedisease activity score 28-count erythrocyte sedimentation rate (ESR) at baseline (odds ratio [OR]: 4.298) was associated with progression of MDI.But multivariate logistic regression revealed that there was no association with the progression of MDI. Univariate analysis revealed that ESR atbaseline (OR: 0.967) and matrix metalloproteinase-3 (MMP-3) at baseline (OR: 0.996) were associated with the progression of UMI. Multivariate logisticregression revealed that MMP-3 at baseline (OR: 0.994) was independently associated with the progression of UMI. Conclusion: Medial displacement index and UMI correlated with the Larsen grade of the shoulder joint strongly and moderately, respectively. Thisstudy suggests that MDI and UMI may help to evaluate radiographic progression of damage in shoulder joints in patients on bDMARDs, which isdifficult to detect using the Larsen grade.

🔖

Cite This Article

SUGİMORİ, K., MATSUSHITA, I., KIMURA, T. (2022). Evaluating various radiographic methods of shoulder joint damage inpatients with rheumatoid arthritis receiving biologicaldisease-modifying antirheumatic drugs. Archives of Rheumatology, Cilt: 36 - Sayı: 3, 349–359. https://ajindex.com/articles/448005

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cuomo F, Greller MJ, Zuckerman JD. The rheumatoid shoulder. Rheum Dis Clin North Am 1998;24:67-82
  2. Thomas T, Noël E, Goupille P, Duquesnoy B, Combe B; GREP. The rheumatoid shoulder: current consensus on diagnosis and treatment. Joint Bone Spine 2006;73:139-43
  3. Shidara K, Inoue E, Hoshi D, Tanaka E, Seto Y, Nakajima A, et al. The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients. J Rheumatol 2012;39:476-80
  4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
  5. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602
  6. Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H, et al. Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 2009;28:453-60
  7. Matsushita I, Motomura H, Seki E, Kimura T. Radiographic changes and factors associated with subsequent progression of damage in weight-bearing joints of patients with rheumatoid arthritis under TNFblocking therapies-three-year observational study. Mod Rheumatol 2017;27:570-5
  8. Hirooka A, Wakitani S, Yoneda M, Ochi T. Shoulder destruction in rheumatoid arthritis. Classification and prognostic signs in 83 patients followed 5-23 years. Acta Orthop Scand 1996;67:258-63
  9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
  10. Miyasaka N, Takeuchi T, Eguchi K. Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol 2005;15:4-8
  11. Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol 2006;16:63-7. 12. van der Heijde DM, van ‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916- 20
  12. Prevoo ML, van ‘t Hof MA, Kuper HH,